Archives

Archive for June, 2014

an ill-gotten fortune…

First off, I realize I’m stuck in a loop. I can’t seem to get away from the European Medicines Agency’s U Turn on Data Transparency. So I guess I’ll be stuck here until I’m not – because that didn’t just happen – it was orchestrated and we know who did it and a bit about […]

in the shadows…

Back in July of last year, we were treated to a leaked memo from PhRMA and EFPIA outlining a broad strategy to fight the EMA Data Transparency initiatives [a closing argument…]. It was reported in the Guardian [Big pharma mobilising patients in battle over drugs trials data] and is shown here as a reminder [read […]

fore·told…

Are Children Overmedicated? Director’s Blog: NIMH By Thomas Insel June 6, 2014 A recent symposium at the Carter Center featured a report by the Centers for Disease Control and Prevention [CDC] that as many as 10,000 toddlers may be receiving psychostimulant medication, like methylphenidate [Ritalin]. The media reports of this, like many past reports, decried […]

some further information…

In the timeline of the European Medicines Agency progress towards a Data Transparency, there was a rather large bump. They were freely releasing the Clinical Study Reports, some two million pages, when two US companies [AbbVie and InterMune] filed suit to prevent data release, and the European Court suspended the data release pending resolution. After […]

awaiting further information…

Press Release European Medicines Agency June 12, 2014 European Medicines Agency agrees policy on publication of clinical trial data with more user-friendly amendments EMA Management Board to formally adopt policy in coming weeks The European Medicines Agency Management Board on 12 June 2014 agreed the policy on publication of clinical trial data, together with more […]

an opinion…

I bookmarked this back during the holidays because of the parts that are highlighted, but that was back when we thought that the EMA Data Transparency was settled, but awaiting the resolution of the AbbeVie/InterMune suits [see a deal-breaker?…]. Running across it today, I can see why I flagged it: Drugmakers urge FDA security audit […]

after all, the point…

Ever wonder how we knew if a treatment helped people or not before Randomized Clinical Trials? Seems almost imponderable to think about, but it was pretty easy. We just asked them. In this meta-analysis of the antidepressant trials of SSRIs in children and adolescents, Spielmans and Gerwig compiled the subjects own ratings of how they […]

tomorrow…

Tomorrow, and tomorrow, and tomorrow, Creeps in this petty pace from day to day, To the last syllable of recorded time; And all our yesterdays have lighted fools The way to dusty death… Macbeth by Wiliam Shakespeare Growing concerns over medicines agency’s proposed rules for transparency EurActiv by Henriette Jacobsen June 11, 2014 A growing […]

non-negotiable…

A guest post by Dr Ben Goldacre: Why are the results of clinical trials hard to find?… Dr Ben Goldacre, author of Bad Science and Bad Pharma, has written us a piece exposing crazy new European Medicines Agency policies on clinical drug trials… usvsth3m by Ben Goldacre June 11, 2014 Tough regulations, like a ban […]

spellbound…

In 1962, I was in college and even though I was applying to medical school at the time, the Kefauver·Harris Amendment  to the Federal Food, Drug, and Cosmetic Act was hardly on a college guy’s radar. But I sure knew about Frances Kelsey PhD, the FDA Reviewer who refused to approve Thalidomide and became a […]